Scopus Biopharma Inc. (SCPS): Price and Financial Metrics


Scopus Biopharma Inc. (SCPS): $0.13

0.03 (+35.42%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SCPS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SCPS Stock Price Chart Interactive Chart >

Price chart for SCPS

SCPS Price/Volume Stats

Current price $0.13 52-week high $1.25
Prev. close $0.10 52-week low $0.06
Day low $0.10 Volume 1,942
Day high $0.13 Avg. volume 39,312
50-day MA $0.15 Dividend yield N/A
200-day MA $0.32 Market Cap 2.74M

Scopus Biopharma Inc. (SCPS) Company Bio


Scopus BioPharma Inc. develops therapeutics drugs targeting the endocannabinoid system. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December, 2017. The company was incorporated in 2017 and is based in New York, New York.


SCPS Latest News Stream


Event/Time News Detail
Loading, please wait...

SCPS Latest Social Stream


Loading social stream, please wait...

View Full SCPS Social Stream

Latest SCPS News From Around the Web

Below are the latest news stories about SCOPUS BIOPHARMA INC that investors may wish to consider to help them evaluate SCPS as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting off the final trading day this week with a look at the biggest pre-market stock movers to watch for Friday!

William White on InvestorPlace | December 16, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday!

William White on InvestorPlace | December 15, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time for another dive into the biggest pre-market stock movers as we check out the latest news traders need to know about on Wednesday!

William White on InvestorPlace | December 7, 2022

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet BioTherapeutics, today announced that key scientific data will be will be presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer (“SITC”). SITC is being held from November 8-12, 2022 at the Boston C

Yahoo | November 10, 2022

Scopus Biopharma Completes Recapitalization Designed To Enhance Shareholder Value

Warrants to Purchase Approximately 21 Million Scopus Shares Eliminated Scopus BioPharma’s Pure Play Immuno-Oncology Subsidiary, Duet BioTherapeutics, Independently Valued at $25 Million Scopus Maintains Approximately 90% Ownership Stake in Duet Duet Being Positioned to Go Public in 2023 NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, a

Yahoo | October 18, 2022

Read More 'SCPS' Stories Here

SCPS Price Returns

1-mo 33.33%
3-mo -49.12%
6-mo -69.36%
1-year -88.50%
3-year N/A
5-year N/A
YTD 33.33%
2022 -94.04%
2021 -88.98%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6371 seconds.